Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

Deciphera Pharmaceuticals, Inc. (DCPH) reported fourth-quarter 2023 loss of 54 cents per share, narrower than the Zacks Consensus Estimate of a loss of 58 cents. In the year-ago quarter, DCPH had incurred a loss of 60 cents per share.Net revenues were $48.3 million, which beat the Zacks Consensus Estimate of $46 million. The figure rose almost 33% year over year.Quarter in DetailTotal revenues comprise net product and collaboration revenues for Qinlock (ripretinib). Deciphera’s sole marketed drug, Qinlock, ...